MedTrace Logo

Endostar Combined With Concurrent Chemoradiotherapy For Locally Advanced Cervical Carcinoma

NCT03086681 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 120

Last updated 2025-07-29

No results posted yet for this study

Summary

A total of 120 patients with pathologically confirmed Locally advanced cervical carcinoma were enrolled. Patients were randomly divided into two groups, with 60 patients in each group. One group was treated with Concurrent Chemoradiotherapy combined with Endostar and the other group was treated with Concurrent Chemoradiotherapy. The short term efficacy and the toxic of these treatments were evaluated. The 1-year, 3-year, 5-year overall survival and progression-free survival of patients were analyzed. The investigators data may provide an alternative option for the treatment of Locally advanced cervical carcinoma with high efficacy and low toxicity.

Conditions

  • Cervical Carcinoma

Interventions

DRUG

Endostar

Endostar: 7.5mg/m2 d1-10, repeat every 15 days, for 4 cycles

DRUG

DDP

DDP: 40mg /m2，per week, for 5 cycles

Sponsors & Collaborators

  • Yong Zhang,MD

    lead OTHER

Principal Investigators

  • Yong Zhang, MD · First Affiliated Hospital of Guangxi Medical University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-04-20
Primary Completion
2020-09-30
Completion
2020-09-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03086681 on ClinicalTrials.gov